Avelumab and Merkel Cell Carcinoma: Examining the Evidence for Causation

From General Health Literacy to Occupational Exposure Concerns

General health and science communication has long emphasized the importance of understanding how environmental and pharmaceutical factors can influence disease risk. Within this broad context, public health messaging has historically focused on lifestyle, infectious agents, and occupational hazards as primary drivers of illness. As scientific inquiry deepens, attention has increasingly turned to the role of specific therapeutic agents in altering disease patterns, particularly in vulnerable populations. This legacy of health surveillance provides a foundation for examining emerging concerns in occupational settings. One such area involves the use of immunomodulatory drugs, including checkpoint inhibitors like Avelumab, which are administered in clinical environments. While these therapies are designed to treat certain cancers, their introduction into the workplace—through manufacturing, handling, or administration—raises questions about potential unintended health effects. Specifically, the possibility that Avelumab exposure could be linked to Merkel cell carcinoma risk represents a shift from general health education toward targeted occupational exposure assessment. Thus, the transition from broad health literacy to focused occupational inquiry requires careful consideration of how pharmaceutical agents, once viewed solely as therapeutic tools, may also present exposure hazards. This pivot underscores the need for rigorous monitoring and risk communication in settings where workers encounter such compounds, moving beyond patient-centered narratives to include occupational health perspectives.

Avelumab as a Therapeutic Agent: Mechanism and Approved Use

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Evaluating the Claim of Causation: Evidence Review

The query posits a causal link between avelumab and Merkel cell carcinoma. However, the available evidence does not support a causative relationship in which avelumab induces or causes MCC. Instead, the evidence consistently describes avelumab as a treatment for MCC, not a trigger. For example, avelumab is approved for the treatment of metastatic MCC and has shown promising ongoing responses in clinical trials (https://pubmed.ncbi.nlm.nih.gov/31543781/). The evidence also discusses avelumab-refractory MCC, referring to patients whose disease progresses despite avelumab therapy, and explores subsequent treatment options such as ipilimumab plus nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). These studies do not suggest that avelumab causes MCC; rather, they address the management of MCC when it becomes resistant to avelumab. Regarding mechanistic pathways, the evidence describes avelumab as an anti-PD-L1 inhibitor that works by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that avelumab can trigger immune-related adverse events, but these are distinct from causing the primary malignancy.

Risk Communication and Implications for Affected Populations

Risk considerations include the adequacy of warnings regarding avelumab and MCC. The evidence indicates that avelumab is approved for MCC treatment, and its prescribing information likely includes warnings about immune-related adverse events, as is standard for checkpoint inhibitors. However, the evidence does not provide specific details about the content of warnings. For affected patients, causation-related considerations are critical: there is no evidence that avelumab causes MCC. Instead, patients with MCC are treated with avelumab, and those who are refractory to it may require alternative therapies. The timeline between exposure and documented harm is relevant only in the context of treatment response or adverse events. For example, in the JAVELIN Merkel 200 trial, objective responses were observed in approximately one-third of patients, indicating a timeline of weeks to months for therapeutic effect (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune-related adverse events, such as the reported case of sarcoidosis reactivation, can occur during treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/). There is no evidence of a timeline linking avelumab exposure to the development of MCC. In summary, the evidence does not support a causal link between avelumab and Merkel cell carcinoma. Avelumab is a treatment for MCC, not a cause. The evidence highlights its efficacy in treating metastatic MCC, the occurrence of immune-related adverse events, and the management of avelumab-refractory disease. Risk communication should accurately reflect that avelumab is a therapeutic agent for MCC, and any warnings should focus on its known adverse effects, such as immune-related events, rather than suggesting it causes the disease it is intended to treat.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the available evidence does not support a causal link between avelumab and Merkel cell carcinoma. Avelumab is a treatment for MCC, not a cause. It is approved for treating metastatic MCC and works by blocking PD-L1 to enhance the immune response against cancer cells.

What is the mechanism of action of avelumab?

Avelumab is a fully human IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1), thereby blocking the interaction between PD-L1 and its receptors. This enhances the immune system's ability to attack cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the known adverse effects of avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. These may include conditions such as sarcoidosis reactivation, as reported in one case (https://pubmed.ncbi.nlm.nih.gov/31543781/). Standard prescribing information includes warnings about irAEs.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.